Alembic Pharma U.S. business lifted by volume growth and new launches
In short
Alembic Pharma said its U.S. business was helped by strong volume growth and new launches in the quarter. The company also said its U.S. branded products are seeing better traction.
What the reporting says
Alembic Pharma’s U.S. business was driven by strong volume growth and new launches in the quarter, according to the company’s comment. In U.S. branded products, the company said traction is building across its existing portfolio. The update follows a reported 81% jump in quarterly net profit to ₹335 crore, highlighting the contribution from its U.S. operations.
Why it matters
Alembic Pharma said its U.S. business was driven by strong volume growth and new launches, and that its U.S. branded portfolio is seeing traction. The comment follows a reported 81% rise in quarterly net profit to ₹335 crore. The update points to the U.S. market as an important growth driver for the company.